Data shows that Amylin-Leptin co-administration reduces body weight and body fat
Amylin Pharmaceuticals, Inc. announced study results showing that co-administration of two neurohormones known to have a role in body weight control, amylin (produced by beta cells in the pancreas) and leptin (produced by fat cells), resulted in sustained, fat-specific weight loss in a leptin-resistant animal model of obesity.
"These findings provide preclinical proof of concept that amylin can restore leptin responsiveness in obese leptin-resistant animals. The study further demonstrates the potential to treat obesity with a combination therapy that employs multiple weight-regulating neurohormones," said Alain Baron, Senior Vice President, Research, at Amylin Pharmaceuticals. "A clinical study to further substantiate these results is planned to start later this year."
In leptin-resistant, diet-induced obese rats, co-administration of amylin and leptin resulted in a decrease in food intake and body weight greater than that seen with either hormone. The amylin plus leptin combination also increased fat oxidation (fat stores used up) and prevented the fall in energy expenditure (calories used up) that is usually expected with weight loss. Weight loss occurred due to decreased fat mass, while lean tissue was preserved.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
